Judi Bryant

1.9k total citations · 1 hit paper
23 papers, 1.6k citations indexed

About

Judi Bryant is a scholar working on Molecular Biology, Organic Chemistry and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Judi Bryant has authored 23 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Organic Chemistry and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Judi Bryant's work include Antiplatelet Therapy and Cardiovascular Diseases (5 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Signaling Pathways in Disease (3 papers). Judi Bryant is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (5 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Signaling Pathways in Disease (3 papers). Judi Bryant collaborates with scholars based in United States, Saudi Arabia and Germany. Judi Bryant's co-authors include Donald J. Cram, Carolyn B. Knobler, Enrico Dalcanale, Roger C. Helgeson, Linda M. Tunstad, John A. Tucker, John C. Sherman, Jürgen Weiser, John R. Moran and Marco Vincenti and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Biochemistry.

In The Last Decade

Judi Bryant

23 papers receiving 1.5k citations

Hit Papers

Host-guest complexation. 48. Octol building blocks for ca... 1989 2026 2001 2013 1989 100 200 300 400

Peers

Judi Bryant
Leo C. Groenen Australia
Judi Bryant
Citations per year, relative to Judi Bryant Judi Bryant (= 1×) peers Leo C. Groenen

Countries citing papers authored by Judi Bryant

Since Specialization
Citations

This map shows the geographic impact of Judi Bryant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judi Bryant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judi Bryant more than expected).

Fields of papers citing papers by Judi Bryant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judi Bryant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judi Bryant. The network helps show where Judi Bryant may publish in the future.

Co-authorship network of co-authors of Judi Bryant

This figure shows the co-authorship network connecting the top 25 collaborators of Judi Bryant. A scholar is included among the top collaborators of Judi Bryant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judi Bryant. Judi Bryant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Islam, Imadul, Shendong Yuan, Christopher W. West, et al.. (2018). Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorganic & Medicinal Chemistry Letters. 28(20). 3372–3375. 4 indexed citations
2.
Islam, Imadul, Shendong Yuan, Wei Xu, et al.. (2018). Reversible, orally available ADP receptor (P2Y12) antagonists Part I: Hit to lead process. Bioorganic & Medicinal Chemistry Letters. 28(9). 1459–1463. 7 indexed citations
3.
West, Christopher W., Marc Adler, Elena Ho, et al.. (2009). Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA). Bioorganic & Medicinal Chemistry Letters. 19(19). 5712–5715. 11 indexed citations
4.
Adler, Marc, Brad O. Buckman, Judi Bryant, et al.. (2008). Structures of potent selective peptide mimetics bound to carboxypeptidase B. Acta Crystallographica Section D Biological Crystallography. 64(2). 149–157. 17 indexed citations
5.
Post, Joseph, Yixin Wang, Jon Vincelette, et al.. (2008). Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization. Thrombosis Research. 122(4). 533–540. 27 indexed citations
6.
Bryant, Judi, Joseph Post, Yixin Wang, et al.. (2008). Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets. Thrombosis Research. 122(4). 523–532. 26 indexed citations
7.
Islam, Imadul, Greg Brown, Judi Bryant, et al.. (2007). Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517. Bioorganic & Medicinal Chemistry Letters. 17(14). 3819–3825. 35 indexed citations
8.
Islam, Imadul, Judi Bryant, Monica J. Kochanny, et al.. (2007). Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity. Bioorganic & Medicinal Chemistry Letters. 17(14). 3814–3818. 42 indexed citations
9.
Vincelette, Jon, Cornell Mallari, Richard M. Fitch, et al.. (2007). A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thrombosis and Haemostasis. 97(5). 847–855. 36 indexed citations
10.
Islam, Imadul, Judi Bryant, Karen May, et al.. (2006). 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorganic & Medicinal Chemistry Letters. 17(5). 1349–1354. 25 indexed citations
11.
Feldman, Richard I., James M. Wu, Mark A. Polokoff, et al.. (2005). Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1. Journal of Biological Chemistry. 280(20). 19867–19874. 171 indexed citations
12.
Adler, Marc, Judi Bryant, Brad O. Buckman, et al.. (2005). Crystal Structures of Potent Thiol-Based Inhibitors Bound to Carboxypeptidase B,. Biochemistry. 44(26). 9339–9347. 26 indexed citations
13.
Cram, Donald J., et al.. (1992). Host-guest complexation. 62. Solvophobic and entropic driving forces for forming velcraplexes, which are 4-fold, lock-key dimers in organic media. Journal of the American Chemical Society. 114(20). 7748–7765. 183 indexed citations
14.
Bryant, Judi, Michael T. Blanda, Marco Vincenti, & Donald J. Cram. (1991). Host-guest complexation. 55. Guest capture during shell closure. Journal of the American Chemical Society. 113(6). 2167–2172. 98 indexed citations
15.
Moran, John R., et al.. (1991). Vases and kites as cavitands. Journal of the American Chemical Society. 113(15). 5707–5714. 228 indexed citations
17.
Bryant, Judi, Michael T. Blanda, Marco Vincenti, & Donald J. Cram. (1990). Shell closures of tetrabenzyl chloride cavitands with tetrabenzylthiol cavitands provide carceplexes in which one or two guest molecules are incarcerated. Journal of the Chemical Society Chemical Communications. 1403–1403. 24 indexed citations
18.
Bryant, Judi, Carolyn B. Knobler, & Donald J. Cram. (1990). Organic molecules dimerize with high structural recognition when each possesses a large lipophilic surface containing two preorganized and complementary host and guest regions. Journal of the American Chemical Society. 112(3). 1254–1255. 57 indexed citations
19.
Bryant, Judi, Siew Peng Ho, Carolyn B. Knobler, & Donald J. Cram. (1990). Host-guest complexation. 54. Spherands containing cyclic urea units. Journal of the American Chemical Society. 112(15). 5837–5843. 19 indexed citations
20.
Tunstad, Linda M., John A. Tucker, Enrico Dalcanale, et al.. (1989). Host-guest complexation. 48. Octol building blocks for cavitands and carcerands. The Journal of Organic Chemistry. 54(6). 1305–1312. 444 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026